Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis.
Stefano GentileschiDonato RiganteJurgen SotaGiuseppe LopalcoMaria Grazia GiannottaGiacomo EmmiGerardo Di ScalaFlorenzo IannoneClaudia FabianiBruno FredianiClaudia FabianiPublished in: Mediators of inflammation (2020)
In our cohort, SCK has proved a remarkable effectiveness regardless biologic treatment line and dosages employed. As suggested by the notable drug retention rate, SCK has been able to maintain its effectiveness over a considerable long period of treatment.